Introduction {#Sec1}
============

The introduction of biologic therapies approximately 20 years ago resulted in unparalleled benefits for the treatment of chronic immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biologic drugs are complex macromolecules produced from living cells that are genetically modified for commercial-scale production and are estimated to account for approximately 32% of global pharmaceutical sales by 2023 \[[@CR1]\]. Remicade^®^ (infliximab) was the first biologic (an originator biologic) on the market for IBD. It is a murine chimeric anti-tumor necrosis factor α (TNFα) monoclonal antibody used for the treatment of RA, ankylosing spondylitis (AS), plaque psoriasis (PsO), psoriatic arthritis (PsA), ulcerative colitis (UC), and Crohn's disease (CD) \[[@CR2]\]. In 2016, global Remicade sales reached almost \$8 billion (USD) \[[@CR3]\]. In addition to market share growth, infliximab has been increasingly used for IBD treatment to prevent UC and CD progression in some countries \[[@CR4]--[@CR7]\].

Over the past 5 years, a number of biosimilars have been approved for use by Health Canada. Biosimilars are biologic therapies that are highly similar, but not identical, to their respective originator biologic products. Although biosimilarity does not require all aspects of the biosimilar and originator products to be the same, biosimilars go through a rigorous comparative pre-approval testing process, where data demonstrating similarity between the originator and biosimilar must be provided \[[@CR8]\]. As such, the type of data to support biosimilars is different than for a stand-alone biologic, and these attenuated clinical trial requirements mean that biosimilars can be offered at a lower price point versus originator molecules. Biologic therapies are complex, microheterogeneous molecules that are highly sensitive to changes in both raw materials and manufacturing conditions. Therefore, small differences exist between biosimilars and their originator products, which may lead to differences in efficacy, safety, or immunogenicity \[[@CR8]\].

CT-P13 (marketed as Inflectra^®^ in Canada and Remsima™ elsewhere) is the first infliximab biosimilar approved in Canada for similar indications as Remicade^®^, except for pediatric UC and CD, based on clinical trials in AS and RA. The availability of this lower-cost alternative may prompt payors to adopt strategies that prioritize biosimilars preferentially over innovator use to reduce healthcare expenditures \[[@CR9]\]. In several countries, non-medical switch from an originator molecule to its biosimilar has emerged as a treatment strategy, typically driven by economic or access reasons. While the safety and efficacy of biosimilar use in infliximab-naïve patients is generally accepted, a "forced switch" to save costs concerns some gastroenterologists, who cite a lack of high-quality controlled trials to support such decisions in stable patients. The objective of this systematic review was to examine the current literature on biosimilar switch and its implications for guiding treatment decisions. To that end, we conducted a systematic review of studies in which patients with CD or UC were switched from infliximab to CT-P13 and reviewed the potential impact on efficacy, response, and safety. The study designs of key randomized clinical trials and observational studies were also critically assessed to contextualize the relevance of the available data.

Materials and Methods {#Sec2}
=====================

The systematic review search strategy was developed to examine the following participants, interventions, comparisons, and outcomes (PICO) items: (P) randomized controlled trials and observational studies of patients diagnosed with CD or UC who were switched to (I) CT-P13 from (C) infliximab and the effect of non-medical switch on (O) efficacy/effectiveness, response, and safety as inferred from disease worsening, loss of response, and sustained remission rate data. This systematic review was not registered with PROSPERO. This systematic review is in accordance with the PRISMA checklist (Table [1](#Tab1){ref-type="table"}).Table 1PRISMA checklistSection/topic\#Checklist item*Title*Title1Identify the report as a systematic review, meta-analysis, or both*Abstract*Structured summary2Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number*Introduction*Rationale3Describe the rationale for the review in the context of what is already knownObjectives4Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS)*Methods*Protocol and registration5Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration numberEligibility criteria6Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationaleInformation sources7Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searchedSearch8Present full electronic search strategy for at least one database, including any limits used, such that it could be repeatedStudy selection9State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)Data collection process10Describe the method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigatorsData items11List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications madeRisk of bias in individual studies12Describe the methods used for assessing the risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesisSummary measures13State the principal summary measures (e.g., risk ratio, difference in means)Synthesis of results14Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2^) for each meta-analysisRisk of bias across studies15Specify any assessment of the risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies)Additional analyses16Describe the methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified*Results*Study selection17Give the numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagramStudy characteristics18For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citationsRisk of bias within studies19Present data on the risk of bias of each study and, if available, any outcome level assessment (see Item 12)Results of individual studies20For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group, (b) effect estimates and confidence intervals, ideally with a forest plotSynthesis of results21Present the main results of the review. If meta-analyses are done, include for each, confidence intervals and measures of consistencyUpdated in accordance with <http://prisma-statement.org/PRISMAStatement/Checklist>Risk of bias across studies22Present results of any assessment of the risk of bias across studies (see Item 15)Additional analysis23Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression \[see Item 16\])*Discussion*Summary of evidence24Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policymakers)Limitations25Discuss limitations at study and outcome level (e.g., risk of bias) and at review level (e.g., incomplete retrieval of identified research, reporting bias)Conclusions26Provide a general interpretation of the results in the context of other evidence and implications for future research*Funding*Funding27Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review

Search Methods {#Sec3}
--------------

A systematic review of the PubMed database was completed in April 2018, using the terms "(((switch OR switching OR interchange OR interchanged \[All Fields\])) AND infliximab \[All Fields\]) AND (ulcerative colitis OR inflammatory bowel disease OR Crohn\[MeSH Terms\])" with no date restrictions, filtered by text availability (only full-text publications were included). Abstracts from the Congress of European Crohn's and Colitis Organization (ECCO, 2013--2018) and Digestive Disease Week (DDW, 2013--2017) via the journal Gastroenterology were searched using the terms "infliximab AND biosimilar AND (inflammatory OR IBD)" and "infliximab AND biosimilar." The absence of a searchable database for United European Gastroenterology Week (UEGW, 2013--2017) required oral and poster abstracts, in portable document format, to be scanned using the term "infliximab."

Selection Criteria {#Sec4}
------------------

Titles and abstracts were identified as potentially eligible by two independent individuals. Studies were eligible if they included data on patients with CD or UC treated with infliximab originator who were stable at the time of switch to CT-P13 and were written in the English language. Appropriate conference abstracts were analyzed to minimize publication bias. UEGW abstracts that included the term "infliximab" were further screened for eligibility criteria, as mentioned above. Review articles, meta-analyses, and other non-clinical papers were excluded. Two individuals then independently examined the full text of the remaining publications and conference abstracts deemed to match the eligibility criteria, with data extracted in duplicate. Any discrepancies were resolved by discussion.

Data Extraction {#Sec5}
---------------

Data were extracted from each relevant report. Each publication was individually reviewed to identify data concerning: study information---primary author, year of publication, title of publication, type of study (randomized or observational); patient characteristics---total number of patients, number of included patients with CD or UC; and study data---interventions, duration of follow-up, efficacy outcomes (disease worsening, loss of response, and sustained remission rates), discontinuation rate, immunogenicity, and safety (adverse effects). Unstated data were designated as non-available (N/A). The extracted data were compiled into evidence tables to facilitate descriptive analysis.

Results {#Sec6}
=======

The literature search identified 2172 potential symposium abstracts and 144 potential publications from PubMed. A total of 27 symposium abstracts and 22 publications were deemed appropriate for final inclusion based on the eligibility criteria outlined in Fig. [1](#Fig1){ref-type="fig"}. This included 5 reports from 3 randomized controlled trials (1 publication; 4 abstracts) and 44 reports from 40 observational trials and 1 case series (21 publications; 23 abstracts), representing a total of 44 distinct studies.Fig. 1Flowchart of literature search outcomes

Evidence from Randomized Controlled Trials {#Sec7}
------------------------------------------

Data from a total of 3 distinct randomized controlled trials were reported in either published articles or abstract format and accounted for just 5 of the 49 publications included in this review. Of these 3 trials, data from the NOR-SWITCH trial were reported in 1 published article and 2 conference abstracts (Table [2](#Tab2){ref-type="table"}). This randomized, double-blind, parallel group, non-inferiority trial evaluated the safety and efficacy of switching from infliximab to CT-P13 versus infliximab maintenance treatment across 6 inflammatory diseases \[[@CR10]\].Table 2Randomized clinical trialsStudyNInterventionDuration of follow-upEfficacy outcomesDiscontinuation rateImmunogenicitySafety*Published studies*Jørgensen KK et al., 2017, Norway(NOR-SWITCH study)*N* = 482*n* = 155 CD*n* = 93 UCMaintenance on IFXSwitch to CT-P1352 weeksDisease worsening:CD: 21.2% in IFX, 36.5% CT-P13UC: 9.1% IFX, 11.9% CT-P13Risk difference:CD: -14.3% (-29.3--0.7)UC: -2.6% (-15.2--10.0)4% of the IFX group and 4% of the CT-P13 group at 52 weeks in the full analysis setNew ADA in 7% of the IFX group and 8% of CT-P13 switch group in the full analysis setNo significant differences in TEAEs, or serious TEAE*Abstracts*Jørgensen KK et al., 2017, Norway(NOR-SWITCH subgroup analysis)*N* = 481*n* = 129 CD*n* = 75 UCMaintenance on IFXSwitch to CT-P1352 weeksCD PtGA: -0.65 (-1.22, -0.07)CD PGA: -0.42 (-0.85, 0.001)N/ANo significant difference in ADA, trough serum levelsNo significant difference in AEsJørgensen KK et al., 2017, Norway(NOR-SWITCH extension trial, subgroup analysis)*N* = 198*n* = 124 CD*n* = 74 UCMaintenance on CT-P13 after DB phaseSwitch to CT-P13 after DB phase26 weeksDisease worsening:CD: 20.6% (13/63) maintenance, 13.1% (8/61) switchUC: 15.4% (6/39) maintenance; 2.9% (1/35) switchN/ANo significant difference in ADA, trough serum levelsNo significant difference in AEsKim YH et al., 2017, International study*N* = 220 CDMaintenance on IFXMaintenance on CT-P13Switch to IFX at week 30Switch to CT-P13 at week 3054 weeksNo significant differences in CDAI-70 at week 54N/ANo significant difference in ADANo significant difference in AEs, infection ratesVolkers AG et al., 2017, Netherlands(SIMILAR trial)*N* = 47*n* = 35 CD*n* = 12 UCMaintenance on IFXSwitch to IFX biosimilar30 weeks1 patient on IFX biosimilar relapsedN/AN/ANo SAEs related to study drug*ADA* antidrug antibodies, *AE* adverse event, *CD* Crohn's disease, *CDAI* Crohn's Disease Activity Index, *DB* double-blind, *IFX* infliximab originator, *N/A* not available, *PGA* physician's global assessment, *PtGA* patient's global assessment, *SAE* severe adverse event, *TEAE* treatment-emergent adverse event, *UC* ulcerative colitis

Patients enrolled in the 52-week NOR-SWITCH trial were ≥ 18 years of age with RA, spondyloarthritis (SpA), PsA, UC, CD, or PsO, and clinically stable on infliximab for ≥ 6 months. The primary endpoint was a composite endpoint of disease worsening, presumably designed to increase event rate and reflect the pragmatic nature of the trial (UC: increase in partial Mayo \[p-Mayo\] score of ≥ 3 and a p-Mayo score of ≥ 5; CD: increase in Harvey-Bradshaw Index \[HBI\] of ≥ 4 and a HBI score of ≥ 7; RA/PsA: increase in Disease Activity Score in 28 joints \[DAS28\] of ≥ 1.2 from randomization and a DAS28 of ≥ 3.2; AS/SpA: increase in Ankylosing Spondylitis Disease Activity Score \[ASDAS\] of ≥ 1.1 and ASDAS of ≥ 2.1; PsO: increase in Psoriasis Area and Severity Index \[PASI\] of ≥ 3 from randomization and a minimum PASI of ≥ 5). A 15% non-inferiority margin was used at 90% power \[[@CR10]\].

The authors concluded that CT-P13 was non-inferior to infliximab based on the disease worsening composite endpoint (29.6% vs. 26.2%, respectively), with a risk difference of − 4.4% (95% confidence interval \[CI\]; − 12.7--3.9) adjusted for diagnosis and treatment duration of infliximab originator at baseline. Independently, results in 5 out of 6 disease categories failed to demonstrate non-inferiority. In CD, the risk difference for switching was − 14.3% (95% CI − 29.3--0.7) \[[@CR10], [@CR11]\]. In UC, disease worsening was observed in 9.1% and 11.9% of switch and infliximab maintenance patients, respectively, with a risk difference of − 2.6% (95% CI − 15.2--10.0) \[[@CR10]\]. However, these analyses should be considered exploratory, as the trial design was not powered to examine subgroups.

Recently, Jørgensen et al. presented an IBD subgroup analysis from the 26-week, NOR-SWITCH open-label extension trial \[[@CR12]\]. Stable switch patients on CT-P13 were enrolled into the maintenance arm after the initial 52-week trial, while those on infliximab maintenance were switched to CT-P13. The primary endpoint was disease worsening according to HBI for CD and the p-Mayo score for UC. Disease worsening occurred in 20.6% versus 13.1% CD patients (risk difference 7.9%, 95% CI − 5.2--21) and 15.4% versus 2.9% UC patients (risk difference 12.4%, 95% CI − 0.1--25) on CT-P13 maintenance versus those switching from infliximab, respectively. Though low enrollment numbers precluded conclusive implications to be drawn, the authors stated that efficacy, safety, and immunogenicity were similar between treatment arms \[[@CR12]\].

The second randomized controlled trial included was presented by Kim et al. at ECCO 2017 (NCT02096861) \[[@CR13]\]. This 54-week, phase III randomized, double-blind, parallel group, non-inferiority trial examined the efficacy and overall safety of CT-P13 versus infliximab in 220 patients with active CD. Patients were randomized to CT-P13 or infliximab and followed for 30 weeks. At week 30, patients in each respective arm were re-randomized to either continue their current therapy or switch, resulting in a total of 4 treatment arms. The primary objective of the study was to compare the efficacy between CT-P13 and infliximab in terms of Crohn's Disease Activity Index-70 (CDAI-70) response rates, defined as a reduction in at least 70 points from baseline CDAI score at week 6. There was no difference in the primary endpoint between arms (CT-P13, 71.4%; infliximab, 75.2%; *p* = 0.5613). The study also examined secondary outcomes associated with CDAI-100 response (reduction in at least 100 points in baseline CDAI score) and clinical remission rates (absolute CDAI score of less than 150 points). Similar trends to CDAI-70 were observed for the more stringent and traditional outcome of CDAI-100 (CT-P13, 61.9%; infliximab, 64.4%; *p* = 0.7744) and clinical remission rates (CT-P13, 42.9%; infliximab, 44.6%; *p* = 0.8329) at week 6 \[[@CR13]\]. A similar proportion of patients between treatment arms were found to have at least one treatment-emergent serious adverse event (CT-P13, 1.8% \[2/111\]; infliximab, 1.8% \[2/109\]) \[[@CR13]\].

Preliminary results of the third and final included randomized controlled trial were presented by Volkers et al. at UEGW 2017 (NCT02452151) \[[@CR14]\]. This randomized, controlled, double-blind, phase IV, non-inferiority trial examined CD and UC patients in clinical and biochemical remission while on infliximab therapy who were randomized to either CT-P13 or infliximab maintenance treatment. The primary endpoint was remission at week 30. A total of 47 patients (35 CD, 12 UC) had been recruited as of October 2017, of whom 21 completed the 30-week follow-up (15 received CT-P13 and 6 infliximab). One patient on CT-P13 experienced a loss of response, and no immunogenicity data were provided. Though preliminary, the authors concluded that switching from infliximab to the biosimilar is feasible and safe \[[@CR14]\].

Evidence from Published Observational Switch Studies {#Sec8}
----------------------------------------------------

Published observational studies accounted for 21 of the total 49 reports included in this review. Due to the significant inter-study heterogeneity of the patient populations, baseline characteristics, dosing schedules, and follow-up periods, a meaningful comparison between the published observational switch studies becomes difficult to conduct and interpret. For example, 6 out of 21 published observational studies (Table [3](#Tab3){ref-type="table"}) reported a loss of effectiveness over the study period for both CD and UC patient populations, with values ranging from 6.3 to 30.2% and 0 to 22%, respectively \[[@CR15]--[@CR20]\]. Five studies reported a loss of response for IBD switch groups as a whole, varying from 0 to 24.6% \[[@CR21]--[@CR25]\]. The observational study by Ratnakumaran et al. was the only one that utilized a control group on infliximab maintenance therapy and also reported on the secondary loss of response post-switch. The authors concluded that observed inter-arm differences were statistically insignificant \[[@CR22]\]. Discontinuation rates were reported for 12 out of 21 studies and ranged from 3 to 27% for the IBD switch groups and 9 to 37% and 19.4 to 43% for CD and UC switch groups, respectively \[[@CR16], [@CR19]--[@CR21], [@CR24]--[@CR31]\]. Immunogenicity and safety data across the studies were diverse, but often lacked a control arm for comparison \[[@CR15]--[@CR35]\]. This variability makes it difficult for broad generalizations regarding the safety and effectiveness of non-medical switch to be made.Table 3Published observational studiesStudy*N*InterventionDuration of follow-upEffectiveness of medicationResponse and/or remission criteriaDiscontinuation rateImmunogenicitySafetyAvouac J et al., 2018, France*N* = 64*n* = 41 CD*n* = 23 UCSwitch to CT-P133 biosimilar infusionsHBI (baseline; follow-up): 0.83; 0.56PM (baseline; follow-up): 0.71; 0.33No significant change in disease activity scoresN/A22% for CD patients by 3rd infusion; 13% of all IBD at a mean follow-up of 34 weeksNo significant change in serum trough concentration after switchNo SAEsBinkhorst L et al., 2018, The Netherlands*N* = 197*n* = 135 CD*n* = 62 UCSwitch to CT-P1316 weeksLoss of response: 5.5% (n = 11)Increase in disease-related symptoms as established by the physician and/or changes in treatment10%No significant change in serum trough concentration after switch1 severe acute IRRNo SAEs or unexpected AEsFiorino G et al., 2018, Italy and SpainIFX: *n* = 13CT-P13: *n* = 9Switch: *n* = 12Maintenance on IFXInitiated on CT-P13Switch to CT-P13N/AN/AN/AN/A16.7% (2/12) developed ADA after switch to CT-P13;100% cross-reactivity of ADAs between IFX, CT-P13, and SB2N/AKang B et al., 2018, Korea*N* = 74 (pediatric)*n* = 60 CD*n* = 14 UCMaintenance on IFX (n = 36)Switch to CT-P13 (n = 38)1 yearSustained remission rate:IFX: 77.8%,Switch: 78.9% (p = 1.00)Clinical remission lasting for at least 2 years plus mucosal healing identified on 2 consecutive annual follow-up colonoscopiesIFX: 13.9%,Switch: 7.9% (p = 0.649)Therapeutic trough levels:IFX: 90.3%,Switch: 88.6%;New ADA:IFX: n = 2,Switch: n = 127 AEs in IFX vs. 30 in switch groupSchmitz EMH et al., 2018, The Netherlands*N* = 133*n* = 85 CD*n* = 48Switch to CT-P131 yearDisease worsening: 9% (n = 12; with 2 deemed not switch-related)N/A26%3 developed ADAs after switch9.8% discontinued treatment due to AEsStrik A et al., 2018, Belgium and The Netherlands(SECURE study)*N* = 120*n* = 61 CD*n* = 59 UCSwitch to CT-P1316 weeksLoss of responseat 16 weeks:CD: 12%UC: 24%Increase in HBI \> 4 in CD patients and in SCCAI \> 2 in UC patientsN/AGeometric mean ratio of drug concentration (week 16 vs. baseline):CD: 107.6% (97.4--118.8)UC: 110.1% (90% CI 96.0--126.3);3 developed new ADAs after switch6 SAEs, with only 1 (perianal abscess) deemed related to study treatmentArgüelles-Arias F et al., 2017, Spain*N* = 120*n* = 67 switch, 13 naïve CD*n* = 31 switch, 9 naïve UCSwitch to CT-P13 (n = 98)Naïve patients initiated on CT-P13 (n = 22)6 monthsSustained remission rate in switch patients:CD: 87.5% at 3 months, 83.9% at 6 monthsUC: 92% at 3 months, 91.3% at 6 monthsNo need for steroids, surgery or increased dose in both CD and UC switch patientsN/AN/ASAEs in 7.5% of total study populationArgüelles-Arias F et al., 2017, Spain*N* = 98*n* = 67 CD*n* = 31 UCSwitch to CT-P131 yearDisease worsening at 1 year:CD: 30.2%UC: 19%;N/ACD: 9%UC: 19.4%N/ASAEs in 11.2% of patientsSustained remission rates:CD: 83.6% at baseline, 62.7% at 1 yearUC: 80.6% at baseline, 64.3% at 1 yearMaintenance of HBI ≤ 4 in CD patients or PM ≤ 2 in UC patients, without the need for steroids, surgery or increased dose after switchingBuer LCT et al., 2017, Norway*N* = 143*n* = 99 CD*n* = 44 UCSwitch to CT-P136 monthsSustained remission rates:CD: 87% at baseline, 81% at 6 monthsUC: 88% at baseline, 95% at 6 monthsMaintenance of HBI ≤ 4 in CD patients and PM \< 2 in UC patients3%3 developed ADAs after switchRate of IRRs 0.7% (5/750)17 AEs reported, 2 resulting in treatment discontinuationEberl A, et al., 2017, Finland*N* = 62*n* = 32 CD*n* = 30 UCSwitch to CT-P133 biosimilar infusionsNo change in disease activity (HBI, PM score)N/AN/A2 developed ADAs after switch;Trough levels:CD: 5.75 mg/L at baseline, 5.5 mg/L at 3^rd^ infusion (p = 0.05)UC: 5.2 mg/L at baseline, 4.25 mg/L at 3^rd^ infusion (p = 0.019)Rate of IRRs 2.5% (4/156 infusions)Fiorino G et al., 2017, Italy(PROSIT-BIO cohort)*N* = 97*n* = 53 CD*n* = 44 UCSwitch to CT-P136.1 ± 2.2 months(mean ± SD)Kaplan--Meier estimate for the probability of response:94.5% at 8 weeks, 90.8% at 16 weeks, 78.9% at 24 weeksN/AKaplan--Meier estimate for the probability of treatment persistence:100% at 8 weeks, 98.7% at 16 weeks, 92.1% at 24 weeksN/ASAEs in 12.4% of patients; discontinuation due to SAEs in 3.1%IRRs in 7.2% of patients; discontinuation due to IRRs in 2.1%Guerrero Puente L et al., 2017, Spain*N* = 36*n* = 23 CD*n* = 13 UCSwitch to CT-P138.4 ± 3.5 months(mean ± SD)Loss of response: 13.9% (mean time to relapse = 2.4 months);Relapse-free survival at 6 months: 85.7%Increased disease activity as assessed by the clinic, radiology, laboratory and endoscopy findingsN/ANo significant difference in pre- and post-switch drug levels at 8 and 16 weeks of follow-up3 (8.3%) of patients experienced AEs; 1 resulted in treatment discontinuationNo IRR, malignancy or deathKolar M et al., 2017, Czech Republic*N* = 74*n* = 56 CD*n* = 18 UCSwitch to CT-P1356 weeksSustained remission rates: 72.2% at baseline, 77.8% at week 56 (p = 0.55)Maintenance of HBI ≤ 4 in CD patients and PM \< 2 in UC patientsN/AADA positive patients: 9.5% at baseline, 6.0% at week 562 patients with CD discontinued due to AEsRatnakumaran R et al., 2017, UK*N* = 210*n* = 140 CD*n* = 48 FCD*n* = 18 UC*n* = 4 IBD-uSwitch to CT-P13 (n = 191)Maintenance on IFX (n = 19)1 yearLoss of response:Switch: 24.6%IFX: 42.1% (p = 0.10);Sustained remission rate:Switch: 58.1%IFX: 47.4% (p = 0.37)Increased disease activity according to physician's global assessment. Asymptomatic patients in clinical assessment were considered in remissionN/AN/AIncidence of AEs were 0% for the IFX group and 4.7% for the switch group (p = 1.0)Razanskaite V et al., 2017, UK*N* = 143*n* = 118 CD*n* = 23 UC*n* = 2 IBD-uSwitch to CT-P13Up to 1 yearIBD-Control-8 Score: 11 at switch, 14 at 3rd infusion (*p* = 0.041)N/A27% at 1 yearMean ADA levels:Pre: 73.2 ± 83.9 AU/mLPost: 96.1 ± 102.0 AU/mL (p = 0.24); no significant difference in pre- and post-switch trough levelThe most common AEs at 3^rd^ infusion were headaches (17%), joint pain (13.8%) and infections (13.8%)Smits LJT et al., 2017, The Netherlands*N* = 83*n* = 57 CD*n* = 24 UC*n* = 2 IBD-uSwitch to CT-P1352 weeksSustained remission rates: 64% at baseline, 73% at week 52Maintenance of HBI ≤ 4 in CD patients and SCCAI ≤ 3 in UC patients18%2 developed ADAs after switch; trough levels unaffected by switch7% (6) discontinued due to AEsSieczkowska J et al. 2016, Poland*N* = 39 (pediatric)*n* = 32 CD*n* = 7 UCSwitch to CT-P13CD: 8 ± 2.6 months (mean ± SD)UC: 5 ± 3.6 months(mean ± SD)Loss of response:CD: 6.3%UC: 14.2%;Sustained remission rate CD : 69% at baseline, 88% at last infusionN/ACD: 37%UC: 43%N/A2 IRRs after switch, 1 resulting in treatment discontinuation1 UC patient discontinued due to varicella zoster infection after 1^st^ CT-P13 infusionCT-P13 safety profile consistent with IFXSustained remission rate UC : 29% at baseline, 57% at last infusionMean PCDAI (range):At switch: 8.8 (0--35)32 weeks: 6.6 (0--43);Mean PUCAI (range):At switch: 16.4 (0--30)4th infusion: 2 (0--5)Maintenance of PCDAI \< 10 or \< 7.5 without the "height" item in CD patients and PUCAI \< 10 in UC patientsSmits LJT et al., 2016, The Netherlands*N* = 83*n* = 57 CD*n* = 24 UC*n* = 2 IBD-uSwitch to CT-P1316 weeksSustained remission rate:CD: 60% at baseline, 67% at week 16UC: 73% at baseline, 62% at week 16Maintenance of HBI ≤ 4 in CD patients and SCCAI ≤ 3 in UC patients.6%Median trough level: 3.5 μg/ml (range 0--18) at baseline, 4.2 μg/ml (range 0--21) at week 16 (*p* = 0.010); 2 developed ADAs post-switchNo SAEsJung YS et al., 2015, Republic of Korea*N* = 36*n* = 27 CD*n* = 9 UCSwitch to CT-P1354 weeksLoss of response:CD: 7.4%UC: 11.1%Response in CD patients: ≥ 70-point CDAI decrease from baseline and ≥ 25% reduction in total CDAI score;Response in UC patients: 3-point decrease in total Mayo score or 2-point decrease in PM, along with 1-point decrease in rectal bleeding subscore or absolute rectal bleeding subscore ≤ 113.9%N/A1 discontinued due to AEsKang YS et al., 2015, Republic of Korea*N* = 9*n* = 5 CD*n* = 4 UCSwitch to CT-P138 weeksLoss of response:CD: 20%UC: 0%Response in CD patients: \> 70-point decrease in CDAIResponse in UC patients: \> 30% decrease in Mayo score, along with decreased rectal bleeding and endoscopy subscoreN/AN/A1 discontinued due to AEsPark SH et al., 2015, Republic of Korea*N* = 60*n* = 40 CD*n* = 4 FCD*n* = 16 UCSwitch to CT-P1330 weeksDisease worsening:CD: 12.9%FCD: 25%UC: 0%;N/AN/AN/A11.7% of patients receiving 5 mg/kg dose had a TEAE; 6.7% receiving \> 5 mg/kg had a TEAESustained remission rate:CD: 80.6%FCD: 50%UC: 45.5%Maintained absence of draining fistulas in CD patients and as a total PM ≤ 2 in UC patients, with no individual subscore \> 1*ADA* antidrug antibodies, *AE* adverse event, *CD* Crohn's disease, *CDAI* Crohn's disease activity index, *FCD* fistulizing Crohn's disease, *HBI* Harvey-Bradshaw Index, *IBD* inflammatory bowel disease, *IBD-u* unclassified inflammatory bowel disease, *IFX* infliximab originator, *IRR* infusion-related reaction, *N/A* not available, *PCDAI* Pediatric Crohn's disease activity index, *PM* partial Mayo score, *PUCAI* pediatric ulcerative colitis activity index, *SAE* severe adverse event, *SD* standard deviation, *SCCAI* simple clinical colitis activity index, *TEAE* treatment-emergent adverse event, *UC* ulcerative colitis

Evidence from Observational Studies in Conference Abstracts {#Sec9}
-----------------------------------------------------------

Data from observational studies presented as posters or abstracts at the selected international gastroenterology conferences accounted for 23 of the 49 total reports included in this review (Table [4](#Tab4){ref-type="table"}) \[[@CR36]--[@CR58]\]. Similarly to the published empirical data, there was significant heterogeneity in patient populations, concomitant medications, and follow-up periods. Results demonstrated high variability in effectiveness, immunogenicity, and safety, with no studies utilizing an infliximab maintenance control arm. Loss of effectiveness for the combined IBD switch population was specifically highlighted in just 6 out of 23 studies, ranging from 4.2 to 25.0% \[[@CR40], [@CR43], [@CR44], [@CR46], [@CR52], [@CR54], [@CR57]\]. Suk et al. was the only study to clearly specify loss of response in the CD and UC switch populations, at 14% and 33%, respectively \[[@CR58]\]. Variability in the reported discontinuation rates and immunogenicity outcomes was also observed (Table [4](#Tab4){ref-type="table"}).Table 4Observational studies from abstractsStudy*N*InterventionDuration of follow-upEffectiveness of medicationDiscontinuation rateImmunogenicitySafetyDaperno M et al., 2018, Italy*N* = 69*n* = 33 CD*n* = 36 UCSwitch to CT-P13 (n = 54)Biologic-naïve patients started on CT-P13 (n = 15)\<2 yearsN/AN/ANo significant difference in ADA and trough levels between the switch and naïve groupsThe incidence of AEs is reduced in the switch vs. naïve group (p \< 0.05)Guerra Veloz MF et al., 2018, Spain*N* = 167*n* = 116 CD*n* = 51 UDSwitch to CT-P131 yearLoss of response: 15.7%;Sustained remission rate (baseline vs. 1 year):CD: 88.8% vs. 69.7% (p \> 0.05)UC: 84.3% vs. 76.7% (p \> 0.05)9%N/ASAEs reported in 7.2% of patientsHoivic ML et al., 2018, Norway*N* = 143*n* = 99 CD*n* = 44 UCSwitch to CT-P1318 monthsNo significant change in disease activity scores8%1.4% of patients developed ADAs with clinical implications; 4.2% developed transient ADAs without loss of responseN/AIlias A et al., 2018, Hungary*N* = 117*n* = 98 CD*n* = 19 UCReverse switch from CT-P13 to IFX24 weeksN/AN/AN/AN/APetitdidier N et al., 2018, France*N* = 113*n* = 83 CD*n* = 28 UCSwitch to CT-P131 yearLoss of response: 12.4%N/AN/AN/APierik MJ et al., 2018, The Netherlands*N* = 119*n* = 77 CD*n* = 42 UCSwitch to CT-P136 infusionsMean (± SEM) change in disease activity compared with baseline:SCCAI: 0.1 ± 0.3HBI: 0.5 ± 0.7N/AN/A53 AEs, including 3 non-related SAEs (melanoma, subarachnoid hemorrhage, hospitalization with fever)Smits L et al., 2018, The Netherlands*N* = 83*n* = 57 CD*n* = 24 UC*n* = 2 IBD-uSwitch to CT-P132 yearsLoss of response: 12% (n = 10);No significant change in SCCAI or HBI32%No significant change in median drug trough levels;2 developed ADAs after switch8 discontinued CT-P13 due to AEsChoe YH et al., 2017, Republic of Korea*N* = 32 (pediatric)*n* = 25 CD*n* = 7 UCSwitch to CT-P1330 weeksSustained remission rate:CD: 86.4%UC: 100%N/AN/A2 had TEAEs1 TESAE1 had an IRRChoe YH et al., 2017, Republic of Korea*N* = 83*n* = 8 FCD:*n* = 75 CD:Switch to CT-P13N/ASustained remission rate:FCD: 87.5%CD: 80%N/AN/AN/AGuidi L et al., 2017, Italy(PROSIT study)*N* = 680*n* = 373 CD*n* = 307 UCSwitch to CT-P13 (n = 109)TNFi-naïve initiated on CT-P13 (n = 400)Patients with previous biologic exposure initiated on CT-P13 (n = 171)≥2 infusions in switch group; safety analysis up to 1 yearNo efficacy analysis specific for the switch group;Loss of response (whole cohort): 10.3%;Deep remission rate (whole cohort):CD: 57%UC: 50%N/AN/A92 SAEs (13.5%) were reported in whole cohort, leading to discontinuation in 73 patients (10.7%)Huoponen S et al., 2017, Finland*N* = 56*n* = 24 CD*n* = 29 UC*n* = 3 IBD-uSwitch to CT-P1316 weeksNo significant change in HBI or PM scores post-switchN/AN/ANo SAEs observedNugent S et al., 2017, Ireland*N* = 33Switch to CT-P131 yearN/A15%N/AN/ARodriguez Glez GE et al., 2017, Spain*N* = 72*n* = 62 CD*n* = 10 UCSwitch to IFX biosimilar1 yearLoss of response: 5.6%;Sustained remission rate (baseline vs. 1 year): 86% vs. 80.5%9.7%N/A10 patients reported AEs; none resulted in treatment discontinuationSladek M et al., 2017, Italy & Poland*N* = 45 (pediatric)*n* = 38 CD*n* = 7 UCSwitch to CT-P1324--36 weeksNo significant change in disease activity after switch6.7%One patient developed ADA post-switch1 discontinued due to AE with high ADA, which presented before switch to CT-P13Bettey M et al., 2016, UK*N* = 134Switch to CT-P1316 weeksN/A1.5%N/ASimilar incidence of AEs before and after switchDíaz Hernández L et al., 2016, Spain*N* = 72*n* = 62 CD*n* = 10 UCSwitch to IFX biosimilar6 monthsLoss of response:4.2% (1 primary non-response, 2 secondary loss of response);Sustained remission rate:Baseline: 86.1%6 months: 86.1%4.2%N/A5 AEs reported (2 infection, 1 cutaneous injury, 1 cephalea, 1 fever allergic reaction)None discontinued due to AEsGuerra Veloz MF et al., 2016, Spain*N* = 31 UCSwitch to CT-P13IFX Naive6 monthsLoss of response:3 months (total 29 switch/1 naïve): 26.3%6 months (total 15 switch/1 naïve): 30%N/AN/AOnly mild AEs reportedGuerra Veloz MF et al., 2016, Spain*N* = 71 CDSwitch to CT-P13IFX Naive6 monthsLoss of response:3 months (total 60 switch/2 naïve): 27.7%6 months (total 29 switch/2 naïve): 30%N/AN/AOnly mild AEs reportedHamanaka S et al., 2016, Japan*N* = 3*n* = 2 CD*n* = 1 UCSwitch to NK24 weeksSustained remission rate: 100%N/AN/AN/AHlavaty T et al. 2016, Slovak Republic*N* = 12*n* = 10 CD*n* = 2 UCSwitch to CT-P13 (n = 12)Up to 48 weeksLoss of response:24 weeks: 0% (0/12)32 weeks: 12.5% (1/8)48 weeks: 25% (2/8)N/AN/A1 developed psoriasiform dermatitis and discontinued treatmentSieczkowska J et al. 2016, Poland*N* = 16 CD (pediatric)Switch to IFX biosimilar5 infusionsN/AN/A100% (15/15) of patients maintained therapeutic drug levels; 26.7% (4/15) had ADA \> 2 ng/mLN/AKierkus J et al. 2015, Poland*N* = 32 CD (pediatric)Switch to CT-P138 weeksPCDAI (mean \[range\]):At switch: 8.5 (0--35)8 weeks: 7.5 (0--23)N/AN/ANo change in the incidence of mild AEsSuk JY et al. 2015, Republic of Koreaa*N* = 42*n* = 32 CD*n* = 10 UCSwitch to CT-P13≥1 infusionLoss of response:CD: 14%UC: 33%N/AN/AN/A*ADA* antidrug antibodies, *AE* adverse event, *CD* Crohn's disease, *FCD* fistulizing Crohn's disease, *HBI* Harvey-Bradshaw Index, *IBD-u* unclassified inflammatory bowel disease, *IFX* infliximab originator, *IRR* infusion-related reaction; *N/A* not available, *NK* Nippon Kayaku/Celltrion infliximab biosimilar (Japan), *PCDAI* Pediatric Crohn's Disease Activity Index, *PM* partial Mayo score, *PUCAI* Pediatric Ulcerative Colitis Activity Index, *SAE* severe adverse event, *SCCAI* Simple Clinical Colitis Activity Index, *SEM* standard error of mean, *TEAE* treatment-emergent adverse event, *TESAE* treatment-emergent serious adverse event, *TNFi* tumor necrosis factor inhibitor, *UC* ulcerative colitis

Ilias et al. recently presented an abstract addressing the paucity of evidence on reverse switch to infliximab (i.e., switching back to infliximab after initial switch to CT-P13) \[[@CR49]\]. Since 2014, all infliximab-naïve patients, and those who had not been exposed for at least 12 months, were mandated to start CT-P13 in Hungary. In August 2017, policy changes resulted in a mandatory reverse switch for all patients on CT-P13, back to originator infliximab. Data were collected from 117 stable CD and UC patients on CT-P13 maintenance from four IBD centers at the time of the reverse switch and 24 weeks post-reverse switch. Concomitant immunomodulators and steroids were used in 53.8/45.8% and 7.5/37.5% of CD/UC patients at the reverse switch, respectively. All but one patient, who experienced an infusion-related reaction, tolerated the first infusion after the reverse switch.

Evidence from Published Observational Studies with Updated Data in Conference Abstracts {#Sec10}
---------------------------------------------------------------------------------------

Currently, the observational study with the most robust enrollment is for the PROSIT-BIO cohort, which used a structured database that included 547 consecutive CD and UC patients from 31 referral centers treated with CT-P13 \[[@CR24]\]. The majority of these patients were anti-TNFα naïve (*n* = 311), 139 had previous exposure to one or more biologics (median duration of drug holiday was 9 months for infliximab and 10 months for other anti-TNFs), and the remaining 97 were switched from infliximab to CT-P13 therapy (hereafter referred to as switch patients). No control arm was utilized in the study. After a median of 6 months of follow-up, primary failure was observed in 8.1% (35/434) of evaluable patients. In the first 8 weeks, there was no primary failure observed in switch patients (95% CI: 0--3.8%; *p* = 0.005). At 16, 24, and 32 weeks, the effectiveness estimations were 94.5%, 90.8%, and 78.9%, respectively, for the switch patients (log-rank *p* = 0.64), with no commentary offered on the loss of response. The probability for treatment nonpersistence in switch patients was estimated to be 1.3% and 7.9% at weeks 16 and 24, respectively. Serious adverse events were reported in 12.4% of switch patients, leading to discontinuations in 2.1% (2/97) of patients. Infusion reactions occurred in 7.2% of patients, at a rate 3 times more frequent than naïve patients \[[@CR24]\]. Guidi et al. presented updated data for PROSIT-BIO at the 2017 Congress of ECCO, in which 680 patients were enrolled. Primary failure was observed in 8.1% of patients (55/680), while a loss of response occurred in 10.3% (62/680) of all patients. There was no infliximab-specific switch data provided, making it challenging to determine the potential impact of non-medical switch to the biosimilar \[[@CR44]\].

Data on long-term outcomes are usually scarce and typically limited to one year following biosimilar switch. Smits et al. examined the long-term efficacy, safety, and immunogenicity profile of non-medical switch from infliximab to CT-P13 in patients with IBD \[[@CR26]\]. Patients enrolled in this single-center, prospective, open-label study consisted of 57 CD, 24 UC, and 2 "IBD unclassified" patients, who were initially followed for 52 weeks post-switch. No control arm was used in this study. The primary endpoint was a change in disease activity scores at week 52 compared to baseline, as measured by HBI for CD or Simple Clinical Colitis Activity Index (SCCAI) for UC and unclassified IBD. Remission rates were reported to be 64% at baseline and 73% at week 52, with no data provided on the loss of response \[[@CR26]\]. More recently, Smits et al. presented data at the 2018 Congress of ECCO on the effectiveness and safety of switch from infliximab to CT-P13 over a 2-year follow-up period, which represents the longest follow-up of an observational switch cohort currently available in the literature \[[@CR57]\]. At week 104, 53 of 78 (68%) patients remained on CT-P13, while 5 were lost to follow-up. Reasons for discontinuation during years 1 and 2 were disease worsening (*n* = 2 and 5, respectively; total 8%), loss of response (*n* = 5 and 5, respectively; total 12%), and adverse events (*n* = 6 and 2, respectively; total 10%). Median trough levels at baseline and weeks 52 and 104 were 3.6 μg/ml (interquartile range \[IQR\] 1.7--5.5), 3.7 μg/ml (IQR 2.1--5.8), and 3.9 μg/ml, respectively (IQR 2.2--5.7; *p* = 0.664). Antidrug antibodies (ADAs) were present in 5 of 83 (6%) patients at baseline (prior to switching) and in 2 (2%) patients before week 52. No subsequent ADAs were detected up to week 104. The majority of IBD patients (68%) continued CT-P13 beyond 2 years after switching from innovator infliximab \[[@CR57]\].

Discussion {#Sec11}
==========

We conducted a systematic review of randomized controlled trials, observational studies, and case series, in which stable patients with UC or CD were switched from originator infliximab to the CT-P13 biosimilar. In total, 49 reports from 44 distinct studies available up to April 2018 were included, expanding the literature examined on infliximab biosimilar switch presented over the last few years \[[@CR59]--[@CR63]\]. Given the paucity of published data from randomized controlled trials, most systematic reviews on infliximab biosimilar switch have referenced a limited number of observational studies \[[@CR62], [@CR63]\]. Some publications have suggested that the current data support the safety of switching from originator infliximab to biosimilar in IBD patients \[[@CR59], [@CR60]\], whereas others have emphasized the need for studies on bidirectional biosimilar switch, as well as those that use appropriate control arms \[[@CR61]\]. We present a comprehensive review evaluating the impact of switching to CT-P13 on efficacy/effectiveness and safety in CD and UC patients. In addition, this systematic review critically appraises methodologies of the studies generating the data that may influence the decision of switching stable patients from infliximab to CT-P13, and highlights their limitations.

Only 3 of the studies included in this systematic review were found to be randomized controlled trials, with NOR-SWITCH being the only trial fully published to date. Designed as a pragmatic real-life study, NOR-SWITCH examined treatment switch across 6 indications in approximately 500 patients (CD, *n* = 155; UC, *n* = 93; SpA, *n* = 91; RA, *n* = 78; PsO, *n* = 35; and PsA, *n* = 30). Limitations of the study design have been previously discussed \[[@CR64]\]. For example, a composite measure of disease worsening was used, which included 6 highly heterogeneous inflammatory disease states each employing different disease activity measures, varying infliximab dosing regimens, and concomitant therapies. This, in addition to patient inclusion being largely based on a "clinical diagnosis" of stable disease with ill-defined disease-specific criteria, introduces the potential for bias and limits the inferences that can be extrapolated to IBD. The primary endpoint of disease worsening was also estimated to occur in 29.6% of patients treated with CT-P13 versus 26.2% on infliximab therapy. As the total enrollment number allowed for a 15% non-inferiority margin at 90% power, theoretically, 50% of CT-P13-treated patients could experience disease worsening without the primary endpoint being deemed inferior. Finally, while subgroup efficacy analyses were underpowered to detect differences, the trend toward increased disease worsening in CD patients has caused some concern in the gastrointestinal community and a desire for more robust data in IBD patients.

In order to address the potential concerns and limitations of NOR-SWITCH, Kim et al. conducted a double-blind study that enrolled a homogenous patient population with active CD, utilized appropriate control arms, and allowed for dose escalation \[[@CR13]\]. It was the first randomized controlled trial that examined the efficacy and safety of a one-way switch from CT-P13 to infliximab in this patient population and investigated a number of secondary endpoints (e.g., pharmacokinetics, safety, ADA development, and quality of life). Randomization of 220 patients across 4 switch arms results in approximately 55 patients per arm (not accounting for attrition). Assuming a power level of 80% and *p* \< 0.05 for statistical significance, the margin of difference would be approximately 20% at 6 weeks. A more stringent non-inferiority margin of 5--10% would require a larger sample size than the 220 patients included in this trial. This study also utilized CDAI-70 response at week 6 as the primary endpoint \[[@CR13]\]. Standard CDAI assesses remission, not response, typically being measured at weeks 8 or 12, and typically a more stringent definition of CDAI-100 is used for response. It is unclear whether 6 weeks is a sufficient duration for a response signal to manifest and if the shorter duration to primary endpoint creates a bias toward demonstrating non-inferiority.

Volkers et al. are currently conducting the first phase IV, double-blind, randomized, non-inferiority clinical trial comparing IBD patients who were switched from infliximab to CT-P13 \[[@CR14]\]. Inclusion criteria required patients to be in clinical remission (HBI \< 5 and Mayo \< 2) and have a fecal calprotectin \< 250 mg/g. The primary endpoint is the number of patients in remission at week 30. Though utilization of the HBI and Mayo questionnaires to determine remission may facilitate the feasibility of a phase IV trial, it does not allow for endoscopic verification of remission, particularly when switching stable patients.

Real-world data can offer valuable insight into the clinical effectiveness and safety of a therapy, prescribing patterns, and quality of life outcomes. The major disadvantage of these studies is the lack of randomization or appropriate control arms. Efficacy and safety assessments are also unlikely to be as robust as those in randomized controlled trials. Though many patients in published observational switch studies appeared to experience disease control, uncontrolled variables may influence perceived drug--outcome correlations, and models may not entirely account for confounding factors, rendering therapies to be seemingly equivalent. This underscores the caution that must be taken when switching stable IBD patients.

A recent meta-analysis attempted to address these concerns by examining published observational switch studies and analyzing data by disease type and duration of follow-up. Due to the heterogeneity of the patient populations, each analyzed group was comprised of only 1--2 studies, making inferences of the analysis difficult to assess \[[@CR62]\]. The lack of published data has also been a limiting factor for meta-analyses. For instance, among the observational studies included in this systematic review, only half had been published by the time of submission. Unfortunately, this leads to a narrow understanding of important study details, the knowledge of which could affect readers' perception of study results.

The present systematic review has several limitations, including the small number of randomized controlled trials; predominance of observational studies with varying outcome assessments, lack of appropriate controls, and absence of data on loss of response and treatment discontinuation; and scarcity of research on long-term effects of biosimilar switch in CD and UC patients. The inclusion of conference abstracts can also be considered a limitation. While their inclusion may help to minimize publication bias, conference abstracts do not provide a complete description of methods and results to allow an evaluation of the rigor in which the research was conducted. In addition, the risk of bias for individual studies used in this review could not be assessed, as this would be subjective due to the biased nature of observational studies, which make up the majority of the studies included. Since this review mainly provides a critique of the methodologies used to generate the majority of data on biosimilar switch from infliximab to CT-P13, the lack of risk assessment does not affect its conclusions.

To date, the totality of evidence would suggest that switching infliximab patients to CT-P13 is generally safe and effective for most individuals. It remains unclear what the long-term impact is on those who are negatively affected by non-medical switching, the role that immunogenicity may play, and what physicians are willing to consider an acceptable risk.

Impact of Non-medical Switch on Immunogenicity {#Sec12}
----------------------------------------------

ADAs are a common occurrence with anti-TNFα therapies \[[@CR65]\]. Indeed, the pivotal trials from a number of anti-TNFα products have demonstrated that the rate of ADAs ranges from approximately 1 to 30% \[[@CR2], [@CR66]--[@CR69]\]. Despite the propensity of ADA development, there are a number of challenges in terms of their quantification and impact assessment.

A recent European Medicines Agency guideline stated that ADA assays may often bind to the therapeutic product itself and thus require significant modifications to accommodate for inaccurate signals. However, such modifications can decrease the sensitivity and accuracy of the assay \[[@CR70]\]. It has also been suggested that comparative assessment of immunogenicity be comprised of more than incidence rates between originator and biosimilar and include titers and titer distribution \[[@CR71]\]. These factors, combined with the inherent differences within patient populations, hamper the comparability of ADAs across clinical trials.

Above all, the precise factors that cause an immunogenic response in patients are likely due to various treatment-, product-, and patient-related considerations \[[@CR72], [@CR73]\]. Gonczi et al. demonstrated the potential impact of drug holidays on those using infliximab. CD patients exposed to infliximab over 12 months prior to initiating CT-P13 therapy demonstrated significantly reduced clinical response and remission up to week 54 (*p* \< 0.005) and higher ADA levels in early treatment (week 2, *p* \< 0.001). Previously treated UC patients demonstrated significantly reduced clinical remission (*p* ≤ 0.03) and ADA development up to week 6 (*p* \< 0.02) versus infliximab-naïve UC patients \[[@CR74]\]. No differences were observed at weeks 14 or 30. Final one-year results of this study confirmed the clinical impact of previous infliximab exposure and highlighted the increased likelihood to develop infusion reactions \[[@CR75], [@CR76]\].

To date, real-world infliximab switch studies in IBD do not have robust or long-term ADA assessments and are not powered to detect significant differences in immunogenicity. The lack of clarity regarding immunogenicity, combined with the inherent variability in ADA assays and loss of response rates observed thus far, reinforces a need for high-quality studies.

Potential Multiple Switch Scenarios {#Sec13}
-----------------------------------

A number of infliximab biosimilars are likely to gain market authorization over the next few years. Several regulatory agencies have started to establish more stringent guidelines for demonstrating interchangeability between a reference drug and its biosimilar \[[@CR77]\]. However, with very limited data on single reverse switches, and no trials examining multiple switches with infliximab, healthcare practitioners are currently ill-informed of the ADA risks and complications that may arise from frequent non-medical switch due to preferential listing or product tendering.

It is prudent that regulatory bodies take appropriate steps to ensure patient safety in this changing environment, as the existence of multiple infliximab biosimilars would make clinical trials extremely complex, and examination of all product-switch permutations unfeasible. Moreover, the increase in untested exposure to potentially different epitopes of infliximab and its biosimilars (particularly if the structures diverge over time), combined with the variability in patient-related factors, is likely to increase the unpredictability of immune responses \[[@CR64]\].

Conclusion {#Sec14}
==========

Despite the potential limitations of the NOR-SWITCH trial, it is currently the only published randomized controlled trial available to glean insights regarding the non-medical switch. Considering this paucity of well-controlled data, the gastroenterology community has largely based clinical decisions on evidence from heterogeneous patient populations in observational trials, which lack controls. Though the majority of these studies suggest that a non-medical switch is safe and effective for most individuals, healthcare professionals and regulatory bodies should be aware of the limitations of study designs when making inferences about the risks and benefits of switching stable IBD patients. Full publication of additional randomized controlled trials in IBD populations will be critical to further our understanding of the impact that such clinical or economic decisions will have on patients.
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